clinical trials


Study NoStudy TitleEstimated EnrollmentStatus
MEI-003Phase 2 Study of Pracinostat with Azacitidine in Patients with Previously Untreated Myelodysplastic Syndrome
102Active, Not Recruiting
MEI-004Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Garcia-Manero, et al. ASH Annual Meeting (2014) [ Poster ] 
50Active, Not Recruiting
MEI-005Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA
39Active, Not Recruiting
MEI-006Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects
MEI-007Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
MEI-008Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
2010-0319Study of SB939 in Subjects with Myelofibrosis
Quintás Crdama, et al. Leukemia Research (2012) [ Paper ]
SB939-2007-002SB939 in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Razak, et al. British Journal of Cancer (2011) [ Paper ]
SB939-2006-001A Phase I Dose Escalation Study of Oral SB939 Administered Alone or with Azacitidine  
 Arm A: Advanced Solid Tumors
Yong, et al. Annals of Oncology (2011) [ Paper ]
 Arm B: Advanced Hematologic Malignancies
Garcia-Manero, et al. ASH Annual Meeting (2010) [ Poster ]
 Arm C: Myelodysplastic Syndrome
Quintás Cardama, et al. ASH Annual Meeting (2012) [ Poster ]


Study NoStudy TitleEstimated EnrollmentStatus
ME-344-001Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
Bendell, et al. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2013) [ Poster ]
ME-344-002ME-344 Given in Combination with Hycamtin® in Patients with Solid Tumors
Up to 54Active, Not Recruiting

ME-401 (PWT143)

Study NoStudy TitleEstimated EnrollmentStatus
PWT-143Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT143

For more information, please contact us at